24 May 2013
Keywords: fda, extends, review, galvus, months, food, drug
Article | 20 November 2006
The US Food and Drug Administration has extended the regulatory review period for Novartis' antidiabetic Galvus (vildagliptin) by three months,
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 November 2006
23 May 2013
© 2013 thepharmaletter.com